{"name":"Insight Therapeutics, LLC","slug":"insight-therapeutics-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"Free Vaccine","genericName":"Free Vaccine","slug":"free-vaccine","indication":"Other","status":"marketed"},{"name":"HD Fluzone Vaccine","genericName":"HD Fluzone Vaccine","slug":"hd-fluzone-vaccine","indication":"Other","status":"marketed"},{"name":"HD Vaccine","genericName":"HD Vaccine","slug":"hd-vaccine","indication":"Huntington's disease","status":"marketed"},{"name":"Recombinant Influenza Vaccine","genericName":"Recombinant Influenza Vaccine","slug":"recombinant-influenza-vaccine","indication":"Other","status":"marketed"},{"name":"SD Fluzone Vaccine","genericName":"SD Fluzone Vaccine","slug":"sd-fluzone-vaccine","indication":"Seasonal influenza prevention in adults and children","status":"marketed"},{"name":"SD Vaccine","genericName":"SD Vaccine","slug":"sd-vaccine","indication":"Other","status":"marketed"},{"name":"adjuvanted trivalent influenza vaccine","genericName":"adjuvanted trivalent influenza vaccine","slug":"adjuvanted-trivalent-influenza-vaccine","indication":"Seasonal influenza prevention in adults","status":"marketed"}]}],"pipeline":[{"name":"Free Vaccine","genericName":"Free Vaccine","slug":"free-vaccine","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"HD Fluzone Vaccine","genericName":"HD Fluzone Vaccine","slug":"hd-fluzone-vaccine","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"HD Vaccine","genericName":"HD Vaccine","slug":"hd-vaccine","phase":"marketed","mechanism":"HD Vaccine is a therapeutic vaccine designed to stimulate the immune system to target and eliminate cells expressing huntingtin protein, potentially slowing neurodegeneration in Huntington's disease.","indications":["Huntington's disease"],"catalyst":""},{"name":"Recombinant Influenza Vaccine","genericName":"Recombinant Influenza Vaccine","slug":"recombinant-influenza-vaccine","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"SD Fluzone Vaccine","genericName":"SD Fluzone Vaccine","slug":"sd-fluzone-vaccine","phase":"marketed","mechanism":"SD Fluzone Vaccine is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains.","indications":["Seasonal influenza prevention in adults and children"],"catalyst":""},{"name":"SD Vaccine","genericName":"SD Vaccine","slug":"sd-vaccine","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"adjuvanted trivalent influenza vaccine","genericName":"adjuvanted trivalent influenza vaccine","slug":"adjuvanted-trivalent-influenza-vaccine","phase":"marketed","mechanism":"An adjuvanted trivalent influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against three strains of influenza virus.","indications":["Seasonal influenza prevention in adults"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxNeUpIQXNZVy04VUptaGd1dDRMa1YwWjRHQTdsUXg2R1RuV0xlX2g5M1diZFpXNmszX1pIMjJ6SERvcmpaN1RlRmtBSWtITVVMVERMcU55UHVsZzUxTDRoVVhsZ3lpQmJVM2psYzRWZ0ZzbTF1YzJKcUM2WDRXNlJtQTZOb1NXSDJkUW9kZl9iUXE0SDNMX2htMklDd2dGNmlCbkN1c2ZpOVp2VlNzZzItS1ZBSUstclUyQ1IxcHVKYTkwUDQxRl94eVRLZnlRVEN2RGtBbnkyalNINEJucV96Vy1XTXpDWk9IdGdPdWVOVkZadGVvY21hYlRGLTdJSklnNGpuSmNKX0ZwcTJuSmJtbmJhQUtrTmthQkVINmtoWFVUWEU1ZmJZU1IwTklKX3N4Tm5rVGtuN1NMQWFqbFQ1YXh2dVZmWENTemthWm1IZw?oc=5","date":"2026-04-07","type":"regulatory","source":"Barchart.com","summary":"Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeutics, Disease Prevalence, Mechanisms, Market Size, Key Companies | DelveInsight -","headline":"Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeut","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"pipeline","source":"GlobeNewswire","summary":"Pharmaceutical and Biotechnology Royalty Rates Agreements - GlobeNewswire","headline":"Pharmaceutical and Biotechnology Royalty Rates Agreements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxNRi05aEdIV0VBTU1ieFpobTNCaVpYQ1R6VHloYzVsVXpUQlltTFE4UzRKQ0R5cmgza0RMS0ltUUJLbTR0RnBaY3hDbWcwaGZxb18weWYteUJSMEUzb0ppbTVrX1NvdTJqQy16VGlVS0dncGg0bDRTSmQtNlNSc2ZTU19kcEdSNERJMXhGdGM2Zm80Ym5YanFvQ2d2YWo1VHJVWE1aS0k2Uzc2eUhKSDJkNWtBWVMwZ0RjWXI5QnFvMEh3aEwyS3hDYXB1amNHYVkzc3RNQ3MzTEpuSzZZbXk4VTBSLVBDNE8wc2xjdDhWZUt4YUhsS3RCd2tzTHRqajYwVE5rWTJydUZWZTJ4Y1JUcDFLbXBrMmlZX3dVR3JFSFJibnJNZmc2ekUzWQ?oc=5","date":"2026-02-16","type":"trial","source":"GlobeNewswire","summary":"IPSC-derived NK Cells Clinical Trial Pipeline Gains - GlobeNewswire","headline":"IPSC-derived NK Cells Clinical Trial Pipeline Gains","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxNdllHTmdMZk5oVEU2bENpQW1jekw0X3JTbE92N0l2Qmx5Y0p1VUU3RWJYN09ZNDNXTUUyS3FnTExLcXk4YXFpWHhjVDZUNXMzWnkwZmZEZjY0QVZxM2FPSHZkaEJ6eUFJc3dHM3BjYmphS0pXNWdLSWVuaWVTVnZFdUtZbnRxcEpuMGRMR2JkS2NWSzlmb01HTW1Xb09XeTFWVHhjVThqTFdkSmcwTUdKYi1jTGVsbUF6a21iTU1GcmswNXVEd3NDWFo1MG1fbXU0Y1NFSkg5OXpubzZiRXk3NlBwVlA4SkhOSWxCX2wxODFZTHJJeTdLZVdGM0FGOUw5TjM5b0JqeFZGQ0Q3?oc=5","date":"2026-01-08","type":"pipeline","source":"Quiver Quantitative","summary":"China SXT Pharmaceuticals Launches Strategic Artificial Intelligence Insights Initiative to Enhance TCM Product Development and Market Intelligence - Quiver Quantitative","headline":"China SXT Pharmaceuticals Launches Strategic Artificial Intelligence Insights Initiative to Enhance TCM Product Developm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxORExra0pqMmhTQ25YV2ZnYkl4OG05d2x4NXg0eHB4ZUozd2ptMWZvQWFzaGlBN1dIblZjeUZmckpJZGpVTGtBby1oOWtMZm0tNUMteEl6RjlUemtka01oMVhvTlZFeDY1RDc3YVkyRDlIRzE2Qkt1MmNISllONzVlWU1HV2xYQmx2eVc2MUZfX3N2dVhGRHhzMUV1UlRPLWw5b2ROTDA1bTQydzQ?oc=5","date":"2025-11-04","type":"pipeline","source":"Deloitte","summary":"Charting the next wave of growth and innovation in advanced therapies - Deloitte","headline":"Charting the next wave of growth and innovation in advanced therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPc2h3YlMyUFlWQ1BtQ19xaDhPd0tGZE9wT1kzZmFHeVpNaVFOc3NQZmFhd1Vjc1AxSHVBc3d6RDQzMFlOMkZvcjVNZmpxclNUYTY3eFU2VC02bEhJcG9YemhneFdueUhVUWRvdWkyVUw4dGVCVGktLXVuVlBCWVE4aVRuUHBEMjE1RXY2ZzFXR19ITWppbFNNLXFFNHh2a1AwcFJ2MGQzdkRpWWQ4b3hPaVFsa2VKTEc5NGY5OGNpNnhadnpRQW45TmM5a3dTWF9VUUZnd2RLYkpJdw?oc=5","date":"2025-10-27","type":"pipeline","source":"PR Newswire","summary":"Prime Therapeutics to present latest managed care pharmacy insights at AMCP Nexus 2025 - PR Newswire","headline":"Prime Therapeutics to present latest managed care pharmacy insights at AMCP Nexus 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxQT195Um84VEw5TDFnZ0x5N0VydUJ0aDNTVGF1SDVWdjh0bEFwbEtyZzM4R2ZEbENDdTVwQzJSV0ZrUU9JSlVZbTZ5TXlYd3NyYmpXT3pVMzdEUHRuTi1lYURucmpkR2M4bzJTeTFNU05iM3dIX0JNNzdoT1otUWVoT3VZamZrTzA5bmYxaUxmTEMxZVpuWm5aRFlVdmZWeXRxU2lWclBRLXg0eEZndGl6VkxBUGRYWjFHdHp0bU9jdnQ1SmpfLXlOd3dPTkhSMTJPRHdDZlpfMjdHQjNyR21Zd2pnU21aQTNOam1SZUw5ZkNyb19xOUMyc0pxRnl4Z2hnRHdLc19CTkdQSy1EYTdDTFRuYkZYRHE0S2tFYm1TMVI?oc=5","date":"2025-10-14","type":"trial","source":"GlobeNewswire","summary":"Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma - GlobeNewswire","headline":"Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNY1JaSEFaVnFfU1RFUF85NFdPTWVkNWpVR1V5dXIxSnZiUGZZV0w2andLOEdNSXUza3FUbnl2N1dQZThDYTZ0eXV0a2V3c1JSMjJqek5aNzd1MGY1M1JkNmZreDJ3cWpRTXR4aWZTLXF1cEowS0xoMnJla3NSd1BReEhORDNmRmI5U1djd3lwNDB0UG5kM0ZzMmNxXzJpSE9YNXRyWnVuOFVDb09Ocld3djFIZF9qd2RweUNPeE5xWlVxWlZUdXUwMGlKdUg5NXVsa1E?oc=5","date":"2025-07-30","type":"pipeline","source":"PR Newswire","summary":"THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight - PR Newswire","headline":"THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxONjFGNFRLejRrYVdvZk5DbWlVVWNZZlZmUlpoZFUwUnBxb2w2bC04LWwxeDlpbDcxZVFoTG50MTNVTEtkWFYyeHZzRHpNOTEyc0RkbHNLcU5qT1hCNFVKM3lwZ05IaXpsb2wwTXJCVEltbHc0LW5hbHdnWmtwLWFScW9WNmcxVHRQWVBPUGxDMnFSeW1OeC1vS0J3RVU?oc=5","date":"2025-07-16","type":"regulatory","source":"OncLive","summary":"FDA’s Published CRLs Deliver Insight Into the Drug Approval Process - OncLive","headline":"FDA’s Published CRLs Deliver Insight Into the Drug Approval Process","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOY3NfX1kwS0gwUHhPNEY2cnhINUxhZXQ4eE5SaTNYSWs1N1dpajdCU3ZVVm9FSEFZckF2YlZmREhjWHZoVXVEMHhvNWhOSnBjTmpMS00xVm9YXzdOR3BLTkdadVhBemREMW9YUGg1ZUxVRWMyeUdkRE1FYVY0RkJ4ZVByWlVXQXdQVUk5Y1RFUmtLR1BUam1qbXhwZ0NRaWVDWVNIeThhSmphU2gtWVhTWnBCSEw?oc=5","date":"2025-05-21","type":"pipeline","source":"Fortune Business Insights","summary":"METASTATIC CASTRATION-RESISTANT PROSTATE CANCER THERAPEUTICS MARKET TRENDS - Fortune Business Insights","headline":"METASTATIC CASTRATION-RESISTANT PROSTATE CANCER THERAPEUTICS MARKET TRENDS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQb1lsZ2RWLUpQaktSNVhyVGFhMXZEQldCYXNTU284R29HUnM0eThRMnBITG5VNlMzWUNpVTlPdmZzVmN0cGpFVXZZZDJxN0hueHFld1BFYVNsMGx4RUNicVRkOVo3bHNXZDNrTzUyQ2c4WkhHLWNNejViOWJCSzBCWnRkQy1QUnhQWFZXdG9TS1I1S0N3S0FZLUlOOVpxUE1Jd1RqS0pLUkd6OE1qRnZsUi1kaUNGMExPczFNcnhFZw?oc=5","date":"2025-05-19","type":"regulatory","source":"Quantum Zeitgeist","summary":"Basil Systems Launches AI-Powered Insights for Global Drug Label Analysis in Pharmaceuticals - Quantum Zeitgeist","headline":"Basil Systems Launches AI-Powered Insights for Global Drug Label Analysis in Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNT3FrZXh1NnlHM0lBdWt1UE1rTDl1aUNkX1BJdjZFaHNObTV2YVdQQnlRX1FHUWY4b3BMOTVpUW0tOWs4dFRaY21BTUpnaUpfekFhS0FBTC1VUXRQSGJqMkhkcjFneHZQcXJ2eHZSczVkbTAwYm1LdjYwa0VhTElnZUdqc19tcDhfU2dpdm9FOU9aSHkyd2dUbGp2TzhjcERUSzM0UTVEVWFmc28?oc=5","date":"2025-04-29","type":"pipeline","source":"GuruFocus","summary":"Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight - GuruFocus","headline":"Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"marketed":7},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}